当前位置: X-MOL 学术Chem. Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Chemical Reviews ( IF 51.4 ) Pub Date : 2022-02-02 , DOI: 10.1021/acs.chemrev.1c00750
Kyle M Garland 1 , Taylor L Sheehy 2 , John T Wilson 1, 2, 3, 4, 5, 6
Affiliation  

The stimulator of interferon genes (STING) cellular signaling pathway is a promising target for cancer immunotherapy. Activation of the intracellular STING protein triggers the production of a multifaceted array of immunostimulatory molecules, which, in the proper context, can drive dendritic cell maturation, antitumor macrophage polarization, T cell priming and activation, natural killer cell activation, vascular reprogramming, and/or cancer cell death, resulting in immune-mediated tumor elimination and generation of antitumor immune memory. Accordingly, there is a significant amount of ongoing preclinical and clinical research toward further understanding the role of the STING pathway in cancer immune surveillance as well as the development of modulators of the pathway as a strategy to stimulate antitumor immunity. Yet, the efficacy of STING pathway agonists is limited by many drug delivery and pharmacological challenges. Depending on the class of STING agonist and the desired administration route, these may include poor drug stability, immunocellular toxicity, immune-related adverse events, limited tumor or lymph node targeting and/or retention, low cellular uptake and intracellular delivery, and a complex dependence on the magnitude and kinetics of STING signaling. This review provides a concise summary of the STING pathway, highlighting recent biological developments, immunological consequences, and implications for drug delivery. This review also offers a critical analysis of an expanding arsenal of chemical strategies that are being employed to enhance the efficacy, safety, and/or clinical utility of STING pathway agonists and lastly draws attention to several opportunities for therapeutic advancements.

中文翻译:

癌症免疫治疗中 STING 通路激活的化学和生物分子策略

干扰素基因刺激物 (STING) 细胞信号通路是癌症免疫治疗的一个有前途的靶点。细胞内 STING 蛋白的激活触发了多方面免疫刺激分子阵列的产生,在适当的情况下,这些分子可以驱动树突状细胞成熟、抗肿瘤巨噬细胞极化、T 细胞启动和激活、自然杀伤细胞激活、血管重编程和/或癌细胞死亡,导致免疫介导的肿瘤消除和抗肿瘤免疫记忆的产生。因此,正在进行大量临床前和临床研究,以进一步了解 STING 通路在癌症免疫监视中的作用,以及开发该通路的调节剂作为刺激抗肿瘤免疫的策略。然而,STING 通路激动剂的功效受到许多药物递送和药理学挑战的限制。根据 STING 激动剂的类别和所需的给药途径,这些可能包括药物稳定性差、免疫细胞毒性、免疫相关不良事件、有限的肿瘤或淋巴结靶向和/或保留、低细胞摄取和细胞内递送,以及复杂的取决于 STING 信号的强度和动力学。这篇综述简要总结了 STING 通路,重点介绍了最近的生物学发展、免疫学后果以及对药物输送的影响。这篇综述还对不断扩大的化学策略库进行了批判性分析,这些策略被用来提高疗效、安全性、
更新日期:2022-02-02
down
wechat
bug